Rutgers researchers find that patients in treatment for opioid use disorder are more likely to stay in treatment if they participate in multiple outpatient visits early in their care.
An educational campaign by Rutgers and the NJ Department of Corrections is first in nation to use direct-access video to reduce disparities in education about opioid treatment
New research from Tufts University School of Medicine suggests critical changes to the process of transitioning people out of jail while on substance use treatment can reduce opioid deaths among the highly susceptible population.
Phone-based and video-based telehealth visits both helped veterans with opioid addiction stay on buprenorphine medication to treat their opioid use disorder during the pandemic. The findings could inform telemedicine policy.
A study analyzing prescription claims for a drug used to treat opioid addictions found that adolescents and young adults were less likely than usual to get treatment during the COVID-19 pandemic, especially if they were covered by private, commercial health insurance.
New research finds people who were using buprenorphine obtained without a prescription were more likely to remain in treatment for opioid-use disorder, underscoring need to expand access to this medication.
The leading cause of HCV in the U.S. is injection drug use as a result of opioid use disorder (OUD), which has seen a rise in most populations, including pregnant people, in recent years. HCV rates have also risen. Between 2009 and 2019, the overall rate per 1,000 live births of HCV in pregnant people increased from 1.8 to 5.1.
With the reintroduction of powerful narcotic opioids to manage acute pain, surgery can be a make-or-break time for patients in recovery from opioid use disorder (OUD). For those using buprenorphine as part of their recovery process, the stress, anxiety and risk can be amplified if, as is often the case, they are directed to stop using the buprenorphine ahead of their surgery.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD). One in ten of these hospitalized medical or surgical patients have comorbid opioid-related diagnoses.
A systematic review and meta-analysis found that using contingency management (CM) at end-of-treatment improved outcomes on six common clinical problems during medication for OUD (MOUD): psychomotor stimulant use, polysubstance use, illicit-opioid use, cigarette smoking, therapy attendance, and medication adherence.
More than 75% of women with Opioid Use Disorder report having had an unintended pregnancy, but they are less likely to use effective contraception compared to women who do not use drugs. Results from a multi-year trial found that a two-part intervention featuring co-located contraceptive services in opioid treatment programs and financial incentives could offer an effective solution.
After a 2020 Vanderbilt University Medical Center study showed women have a difficult time accessing treatment for opioid use disorder (OUD), investigators analyzed comments received from the study’s participants to further shed light on barriers to care, which included everything from long on-hold times to difficult interactions with clinic receptionists during phone calls seeking appointments.
Lewis Nelson, professor and chair of emergency medicine at the Rutgers New Jersey Medical School, is available to discuss the loosened restrictions in prescribing buprenorphine to treat opioid use disorder, an issue many physicians have advocated for to help reduce…
Among people with opioid use disorder (OUD), more than half have reported contact with the criminal justice system. A new study published today in Health Affairs reveals that Medicaid expansion is associated with substantial improvements in access to medications for OUD. However, the study also reveals that individuals referred for treatment by the criminal justice system were substantially less likely to receive medications for OUD as part of the treatment plan.
The coronavirus pandemic has led to several temporary regulatory relaxations and policy innovations in treatment for opioid use disorder aimed at making it easier for those seeking care to access treatment without risking in-person interactions. The Foundation for Opioid Response Efforts (FORE) today announced it is providing grants totaling $1.3 million to six organizations to assess the impact of these temporary measures and inform future policies to improve access and promote equity for the treatment of opioid use disorder.
In a study at Penn researchers found that Pennsylvania’s financial incentive policy encouraged hospitals to enact rapid changes to support treatment for opioid use disorder for patients visiting the ED, and evaluates the efficacy of the Opioid Hospital Quality Improvement Program.
Study finds no decrease in prescription fills or clinician visits in the first three months of the COVID-19 pandemic for patients recently receiving opioid use disorder therapy.
On the flip side, the study found that during this period fewer people started new treatment for opioid use disorder and fewer urine tests were given across both new and established patients.
Findings identify strengths and weaknesses in telemedicine’s role for opioid use disorder during shutdowns and can inform strategies for improvement.
A Rutgers expert discusses the many impacts of COVID-19 on people with substance use disorder and what treatment providers, policymakers and researchers are doing to help.
A new study suggests that patients with opioid use disorder may be identified using information available in electronic health records, even when diagnostic codes do not reflect this diagnosis. The study demonstrates the utility of proxies coding for DSM-5 criteria from medical records to generate a quantitative DSM-5 score that is associated with opioid use disorder severity. The study methods are unique in deriving a severity score that aims to mirror severity scores from more traditional interview-based diagnostic procedures.
The “secret shopper” study used trained actors attempting to get into treatment with an addiction provider in 10 U.S. states. The results, with more than 10,000 unique patients, revealed numerous challenges in scheduling a first-time appointment to receive medications for opioid use disorder, including finding a provider who takes insurance rather than cash.
Nearly 10 percent of patients who are prescribed opioid medications following heart surgery will continue to use opioids more than 90 days after the procedure, according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Of nearly 6,500 commercially insured patients treated in EDs nationwide for an overdose or other opioid-related medical complications, only 16 percent accessed opioid use disorder (OUD) medications or another form of treatment within three months of the ED visit.
When Kentucky Gov. Andy Beshear announced the early release of some Kentucky inmates due to COVID-19 concerns, the team behind the HEALing Communities Study worked quickly to fast-track one of the evidence-based practices for preventing opioid deaths that was due to launch later this year: the distribution of naloxone to individuals at highest risk for overdose, particularly those being released from local jails.
UAB is launching a pilot program aimed at getting more opioid users into treatment, using telemedicine in three rural counties and emploing the Alabama One Health Record®, a statewide health information exchange, to track outcomes in these patients.
Offering $750 to emergency medicine physicians exponentially increased those trained to prescribe buprenorphine.
A new survey of U.S. primary care physicians from researchers at Johns Hopkins Bloomberg School of Public Health found that nearly one-third, 32.9 percent, do not think treating opioid use disorder with medication is any more effective than treatment without medication.
A new study led by University of Kentucky researcher April Young and Emory University researcher Hannah Cooper shows that a number of pharmacies in the Appalachian region of Kentucky are limiting the dispensing of buprenorphine, a medication used to treat opioid use disorder (OUD).
Patients with opioid use disorder (OUD) receiving treatment with opioid agonists (medications such as methadone or buprenorphine) had an 80 percent lower risk of dying from an opioid overdose compared to patients in treatment without the use of medications.
Proactive outreach, including knocking on the doors of individuals who recently overdosed on opioids, can be an effective way to engage more people who have opioid use disorder with long-term care, according to researchers at UTHealth.
A study of more than 4 million Medicaid claims records during a recent seven-year period concludes that less than a third of the nearly 3,800 U.S. adolescents and young adults who experienced a nonfatal opioid overdose got timely (within 30 days) follow-up addiction treatment to curb or prevent future misuse and reduce the risk of a second overdose.
Two researchers from Penn State College of Medicine have received nearly $5 million from the National Institutes of Health to study whether an already-approved drug can be used to reduce cravings and prevent relapse in those struggling with opioid addiction.
The research team looked at all research on the effects of cannabis use on illicit opioid use during methadone maintenance therapy, which is a common treatment for opioid use disorder, and found six studies involving more than 3,600 participants.
Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million National Institutes of Health study testing treatments, including the use of telemedicine, to help fight the opioid epidemic in rural America.